NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVB and the CUSIP is 63937X202. A total of 26 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $17,812 | -18.6% | 68,507 | -34.2% | 0.00% | – |
| Q4 2022 | $21,871 | +143.0% | 104,149 | +205.4% | 0.00% | – |
| Q3 2022 | $9,000 | -79.5% | 34,100 | -44.7% | 0.00% | – |
| Q2 2022 | $44,000 | +18.9% | 61,617 | +32.9% | 0.00% | – |
| Q1 2022 | $37,000 | -65.1% | 46,362 | -55.9% | 0.00% | – |
| Q4 2021 | $106,000 | -35.8% | 105,062 | +11.3% | 0.00% | – |
| Q3 2021 | $165,000 | -33.5% | 94,437 | -30.6% | 0.00% | – |
| Q2 2021 | $248,000 | +11.2% | 136,143 | +22.9% | 0.00% | – |
| Q1 2021 | $223,000 | +38.5% | 110,814 | +48.2% | 0.00% | – |
| Q4 2020 | $161,000 | +28.8% | 74,795 | +61.9% | 0.00% | – |
| Q3 2020 | $125,000 | -29.0% | 46,192 | +3.6% | 0.00% | – |
| Q2 2020 | $176,000 | +738.1% | 44,598 | +58.6% | 0.00% | – |
| Q1 2020 | $21,000 | +5.0% | 28,127 | -2.7% | 0.00% | – |
| Q3 2019 | $20,000 | +81.8% | 28,915 | +72.4% | 0.00% | – |
| Q2 2019 | $11,000 | – | 16,769 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Allred Capital Management, LLC | 36,838 | $26,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 102,440 | $74,000 | 0.00% |
| PDS Planning, Inc | 10,565 | $8,000 | 0.00% |
| UBS Group AG | 105 | $0 | 0.00% |
| Parallel Advisors, LLC | 350 | $0 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 1,722 | $1,000 | 0.00% |
| WELLS FARGO & COMPANY/MN | 4,954 | $3,000 | 0.00% |
| NORTHERN TRUST CORP | 39,414 | $28,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GROUP ONE TRADING, L.P. | 227,452 | $164,000 | 0.00% |